NVAX Stock Discussion
Novavax, Inc. Description
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Development Infectious Diseases Vaccines Influenza Coronavirus Vaccination Influenza Vaccine Rabies Seasonal Influenza
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Popular Now
Featured Articles